Evidence map›Paper›PMID 37857680›Full record

ArticleScientific reports2023

Viral and immunologic evaluation of smokers with severe COVID-19.

Joseph Vecchio, James Regan, Yuting Jiang, Roy Li, Hannah Romain, Fizah Yousuf, Thomas Adel, Kevin Hall, Jeffrey M DaCosta, Xu Yu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Joseph Vecchio *Biology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, USA.
James Regan *Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yuting JiangBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, USA.
Roy LiBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, USA.
Hannah RomainBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, USA.
Fizah YousufBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, USA.
Thomas AdelBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, USA.
Kevin HallBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, USA.
Jeffrey M DaCostaBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, USA.
Xu YuRagon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA, USA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. JLI@bwh.harvard.edu.
Ismael Ben FofanaBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, USA. ismael.fofana@bc.edu.
Boston College · USBrigham and Women's Hospital · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Smoking negatively affects B cell function and immunoglobulin levels, but it is unclear if this immune dysfunction contributes to the risk of severe COVID-19 in smokers. We evaluated binding IgM, IgA and IgG antibodies to spike and receptor binding domain antigens, and used a pseudovirus assay to quantify neutralization titers in a set of 27 patients with severe COVID-19. We found no significant differences between binding and neutralization antibody responses for people with a smoking history and people who never smoked. High plasma viral load, but not antibody titers, was linked to an increased risk of death. Humoral immune dysfunction was not a major driver of severe COVID-19 in smokers.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralAntibody FormationHumansImmunoglobulin MSARS-CoV-2SmokersAntibodies, NeutralizingAntibodies, ViralImmunoglobulin M

Identifiers

PMID37857680
PMCPMC10587108
OpenAlexW4387769837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.